Top Stories
Oorja Bio launched with $30 million and an idiopathic pulmonary fibrosis candidate, while MaaT expects a negative opinion on its acute graft-versus-host disease candidate in Europe.
The combined firm will back companies across pharmaceuticals, medical devices, life science tools, diagnostics, healthcare infrastructure and healthcare IT.
After 16 weeks, 35.8% of patients taking weekly IMVT-1402 achieved ACR70.
CANOPY-HCH-3 demonstrates significant growth velocity improvement with the modified C-type natriuretic peptide over placebo.
One of the drugmaker's main goals is to make its wealth of scientific, clinical, regulatory and commercial expertise easy to surface.
Conference News
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st...
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatmentThree oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipelineSAN CARLOS, Calif.--...
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no immunogenici...
Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cance...
